Factors affecting time to brain metastases for stage 2 and 3 breast cancer patients: A large single-institutional analysis with potential screening implications.
HER2+ breast cancer
MRI screening
brain metastases
breast cancer
triple negative
Journal
Neuro-oncology advances
ISSN: 2632-2498
Titre abrégé: Neurooncol Adv
Pays: England
ID NLM: 101755003
Informations de publication
Date de publication:
Historique:
entrez:
19
3
2021
pubmed:
20
3
2021
medline:
20
3
2021
Statut:
epublish
Résumé
Breast cancer is the second most common cancer associated with brain metastases. The purpose of this study was to identify factors that impact the time to brain metastases in breast cancer patients at a single institution. Single institution retrospective study that captured all consecutive stage 2 and stage 3 breast cancer patients from 2003 to 2010. Patient characteristics analyzed included age, hormone status, HER2 receptor status, grade, stage, and time from breast cancer diagnosis to brain metastasis. A total of 1218 patients were eligible for the final analysis. 849 (69.7%) patients were ER+/HER2-, 90 (7.4%) were HER2+, and 279 (22.9%) were triple-negative (TN). Overall, 74 patients (6.1%) developed brain metastases over a median follow up time of 92 months. Median times to brain metastases for HER2+, TN, and ER+/HER2- patients were 20, 26, and 57 months, respectively. Multivariate analysis demonstrated that TN disease (HR = 2.043, This single-institutional case series demonstrates that TN breast cancer, higher stage, and higher histologic grade are associated with earlier brain metastases in multivariate analysis. Additional prospective studies are warranted to investigate the impact of brain metastases screening on survival outcome in this high-risk defined group.
Sections du résumé
BACKGROUND
BACKGROUND
Breast cancer is the second most common cancer associated with brain metastases. The purpose of this study was to identify factors that impact the time to brain metastases in breast cancer patients at a single institution.
METHODS
METHODS
Single institution retrospective study that captured all consecutive stage 2 and stage 3 breast cancer patients from 2003 to 2010. Patient characteristics analyzed included age, hormone status, HER2 receptor status, grade, stage, and time from breast cancer diagnosis to brain metastasis.
RESULTS
RESULTS
A total of 1218 patients were eligible for the final analysis. 849 (69.7%) patients were ER+/HER2-, 90 (7.4%) were HER2+, and 279 (22.9%) were triple-negative (TN). Overall, 74 patients (6.1%) developed brain metastases over a median follow up time of 92 months. Median times to brain metastases for HER2+, TN, and ER+/HER2- patients were 20, 26, and 57 months, respectively. Multivariate analysis demonstrated that TN disease (HR = 2.043,
CONCLUSIONS
CONCLUSIONS
This single-institutional case series demonstrates that TN breast cancer, higher stage, and higher histologic grade are associated with earlier brain metastases in multivariate analysis. Additional prospective studies are warranted to investigate the impact of brain metastases screening on survival outcome in this high-risk defined group.
Identifiants
pubmed: 33738445
doi: 10.1093/noajnl/vdab009
pii: vdab009
pmc: PMC7954098
doi:
Types de publication
Journal Article
Langues
eng
Pagination
vdab009Informations de copyright
© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Références
Cancer. 2012 Nov 1;118(21):5198-209
pubmed: 22510844
Breast Cancer Res Treat. 2008 May;109(2):231-9
pubmed: 17638068
JAMA Oncol. 2017 Aug 1;3(8):1069-1077
pubmed: 28301662
Ann Oncol. 2006 Jun;17(6):935-44
pubmed: 16603601
J Neurooncol. 2018 Jun;138(2):369-382
pubmed: 29488184
Breast. 2017 Feb;31:90-98
pubmed: 27829201
J Neurooncol. 2017 Sep;134(2):453-463
pubmed: 28674973
Eur J Cancer. 1993;29A(15):2155-7
pubmed: 8297656
Breast Cancer Res Treat. 2014 Aug;147(1):103-12
pubmed: 25106661
J Neurooncol. 2013 May;112(3):467-72
pubmed: 23462853
Exp Hematol Oncol. 2015 Nov 24;4:33
pubmed: 26605131
Cancer. 1983 Dec 15;52(12):2349-54
pubmed: 6640506
Arch Pathol Lab Med. 2014 Feb;138(2):241-56
pubmed: 24099077
Breast Cancer Res. 2008;10(1):R20
pubmed: 18307763
Ann Oncol. 2008 Sep;19(9):1561-5
pubmed: 18534964
J Thorac Oncol. 2016 Mar;11(3):426-31
pubmed: 26746367
Eur J Cancer. 2009 Nov;45(16):2792-8
pubmed: 19643597
Clin Cancer Res. 2007 Mar 15;13(6):1648-55
pubmed: 17363517
J Clin Oncol. 2014 Jul 1;32(19):2100-8
pubmed: 24799487
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Clin Oncol (R Coll Radiol). 2004 Aug;16(5):345-9
pubmed: 15341438
Cancer. 2008 Nov 15;113(10):2638-45
pubmed: 18833576
Breast Cancer Res. 2016 Jan 19;18(1):8
pubmed: 26781299
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2111-7
pubmed: 21497451
Lancet Oncol. 2013 Mar;14(3):244-8
pubmed: 23414588
J Clin Oncol. 2004 Sep 1;22(17):3608-17
pubmed: 15337811
Br J Cancer. 2012 Jan 31;106(3):440-6
pubmed: 22233926
Cancer. 2003 Jun 15;97(12):2972-7
pubmed: 12784331
Clin Oncol (R Coll Radiol). 2009 Nov;21(9):729-30
pubmed: 19643588
Cancer. 2006 Aug 15;107(4):696-704
pubmed: 16826579